Thomás Alexandre

Thomás Alexandre

[Thomás Alexandre @ThomsAlexandre]

https://t.co/cAibyzXZmX

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Is oligometastatic prostate cancer becoming a distinct therapeutic state—or simply a consequence of better imaging?

Article 📰
https://t.co/LVYtoO3uUm

Oligometastatic prostate cancer — bridging the gap between localized and metastatic disease

Next-generation imaging, particularly PSMA PET–CT, is transforming the identification and management of oligometastatic #ProstateCancer . While metastasis-directed therapy can delay progression and systemic treatment in selected metachronous disease, its role in de novo oligometastatic cancer remains uncertain.

➡️Prostate-directed therapy is also under investigation alongside intensified systemic treatment.
✅Key challenges include defining oligometastatic disease, integrating biological selection, optimizing treatment sequencing, and establishing meaningful clinical endpoints.

@TheGiesen
@EveraertsW
@joniau
@gertmeerleer
@jaspervgou
@karolien_goffin
@GevaertThomas

@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists

[Thomás Alexandre @ThomsAlexandre]

#NovaFotoDePerfil

[Thomás Alexandre @ThomsAlexandre]

The Global Impact of URO-ONCO 2026 https://t.co/HyLQLe9Lxe

[Arndt Vogel @ArndtVogel]

Camrelizumab + rivoceranib vs direct surgery in resectable HCC at intermediate or high risk
@TheLancet
https://t.co/X8xoMllmDf
🔎CARES-009 phs 2/3
👉Perioperative cam + rivo doubles EFS
🧐Consistent pos. data for the combo, will be interesting to see whether & when approved in the West
@myESMO @EASLedu @ILCAnews

[Erman Akkus @Erman_Akkus]

🟠HCC guideline updates from @BCLC_group and @BritSocGastro

👉https://t.co/gYQ8EdBGcZ
👉https://t.co/xyI864VRWR

#cancer #oncology #MedX #liver #HCC @OncoAlert @OncBrothers @SuyogCancer

[Oscar Tahuahua @drtahuahua]

📊 Meta-analysis in mHSPC (>13,000 pts, 11 ph3 trials)

SoC (ADT±chemo) vs SoC + ARPI ± chemo

OS benefit ↓ with age HR 0.63 (<70y) vs 0.82 (≥70y)
Older pts ↑CV toxicity, ↑G3–5 AEs, ↑ discontinuations

In ≥70y low-vol mHSPC w/RT to the primary, ARPI adds little OS gain.
In ≥70y chemo or triplet Tx showed no OS gain

✅Tx choice must be guided by biology & fitness, not by age
https://t.co/cea4V2gVXP @OncoAlert

[Uğur Özkerim @UOzkerim]

💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌
Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪
From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever.
Which one are you most looking forward to? 💬

🌍 Follow the global dream team:

#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc 
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar

[Stephen V Liu, MD @StephenVLiu]

#ELCC25 program includes OS updates from MARIPOSA &amp; LAURA in #EGFR NSCLC, adagrasib + pembrolizumab in #KRAS G12C, &amp; final analysis from KEYNOTE 799 of pembrolizumab + chemoradiation in stage III NSCLC. Educational program highlights include AI session with Dr. @PrelajArsela

[Dr Asma Jabeen @DrasmaJabeen1]

Which tool is your favorite. Keep adding more. Infographic by Dr Faheem Ullah #AcademicTwitter #phdlife #phdchat

[Annals of Oncology @Annals_Oncology]

New article in press: Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. @GroupeUnicancer @icl_lorraine
https://t.co/DlPjBhLzGb

[Kathrin Heinrich @heinrich_kat]

Great work by the team around @FilippoPietran4, @ChiaraCrem1 and @sara_lonardi1 investigating ICI in dMMR #colorectalcancer

👉TMBhigh: excellent response
👉TMBlow: poor response
👉more biomarkers needed for TMB intermediate 🧐

@OncoAlert 🚨

https://t.co/lBveXH6apZ

[Thomás Alexandre @ThomsAlexandre]

QS Ranking 2024 aponta UFRJ como melhor universidade federal do Brasil – Conexão UFRJ https://t.co/c17RkN6dNa

[Yüksel Ürün @DrYukselUrun]

Even though we are in the era of targeted therapies, immunotherapies, and agnostic approaches, let's not forget that chemotherapy is still the cornerstone treatment for many tumors!
@CellCellPress @OncoAlert @OncBrothers @HemOncFellows @ASCO @myESMO
https://t.co/pReIKf9IlW

[Thomás Alexandre @ThomsAlexandre]

👏🏻

[The Innovation | Medicine @Innov_Medicine]

Approach to management of #SCLC #algorithm created by @MatthewHoMD and @ADesaiMD giving 🔍into current Rx, credit @NCCN @JackWestMD and resource for #patients, and #providers @OncoAlert
#MedTwitter #MedEd #Cancer #NurseTwitter
PDF:https://t.co/n6dPln4KfZ

@Innov_Medicine

[Thomás Alexandre @ThomsAlexandre]

Great job 👏🏻

[The Innovation | Medicine @Innov_Medicine]

Approach to management of NSCLC #algorithm created by @MatthewHoMD and @ADesaiMD giving 🔍into current Rx, credit @NCCN
@JackWestMD and resource for #patients, and #providers @OncoAlert @Innov_Medicine
#MedTwitter #MedEd #Cancer #NurseTwitter
PDF:
https://t.co/f3nqJvgC6h

[ASCO @ASCO]

Just issued: 🫁 Updated recommendations on therapy for stage IV #NSCLC with driver alterations ➡️ https://t.co/tSFw4mwGu7 #lungcancer #lcsm

[Vivek Subbiah, MD @VivekSubbiah]

⭐️Molecular classification in endometrial cancer: Opportunities for #PrecisionMedicine in a changing landscape @JournalCancer @OncoAlert 🎯🧬https://t.co/NkGJItghdu